glp 1 cancer prevention glp-1 GLP-1s tied to lower risk for 10 types of compared with insulin in type 2 diabetes GLP-1 Receptor Agonists: Benefits and – GLP-1 Drugs Linked to Dramatically

2012 Feb;35(2):454-84

These factors include systemic inflammation ( In concordance with the above, weight loss of a magnitude obtainable with bariatric surgery, or with newer agents such as semaglutide ( The reductions in ROS and systemic inflammation, in combination with improvements in the other cardiometabolic parameters, are also thought to mediate the substantiated but so far formally unconfirmed kidney-protective effects of GLP-1 RAs, which may also directly or indirectly carry a HF-related benefit, considering that CKD is a prominent risk factor for HF (Table 1), the results of which resembles our and another similar recent analysis ( Direct effects of GLP-1 receptor agonism on the heart is likely not a major contributor

This dual compatibility makes them highly versatile for carrying vitamins, antioxidants, and other bioactives that are otherwise poorly absorbed or unstable in traditional supplement forms

Pharmacol Ther 123:386400 Lo M, Wang YZ, Gout PW (2008) The x(c) cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases

Tate AD, Antonelli PJ, Hannabass KR, Dirain CO